Fenwick Represents Samsara BioCapital in Alumis’ $259M Series C Financing

Fenwick represented Samsara BioCapital, a biotech-focused investment firm, in its investment in Alumis’ $259 million Series C financing. Alumis is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize outcomes and transform the lives of patients with immune-mediated diseases. The round was co-led by Foresite Capital, Samsara BioCapital and venBio Partners with participation from additional new and existing investors.

Alumis will use the funds to support an ongoing comprehensive mid to late-stage clinical development program for ESK-001 in plaque psoriasis, systemic lupus erythematosus (SLE) and uveitis. More information can be obtained from the company’s announcement.

The transaction was led by corporate partners Bill Bromfield and Effie Toshav and associate Sam Millang; and intellectual property partner Carl Morales and associate Stefan Ochiana.